WW Stock Analysis: WW International | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 150m USD | 12M Return: -37.3% | US98262P2002 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.71M
Qual. Beats: 0
Rev. Trend: -99.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
WW International, Inc. (NASDAQ: WW) is a U.S.-based weight management company that offers nutritional, behavioral, and lifestyle products and services across the United States, Germany, Canada, and other international markets. Its subscription tiers include Core for digital weight management, Core+ for unlimited workshop access, and Med+ which connects subscribers to clinicians for prescriptions of GLP-1 medications, hormone replacement therapy, and other treatments relevant to weight management, perimenopause, menopause, and diabetes care. The company also generates revenue through trademark licensing in food, beverages, and adjacent consumer products, as well as publishing services. Originally founded in 1963 as Weight Watchers International, the company rebranded to WW International, Inc. in September 2019 and is headquartered in New York.
The company operates within the Consumer Discretionary sector (GICS Sub Industry: Specialized Consumer Services), a category that includes consumer-facing health, wellness, and personal services businesses. WWs business model blends subscription-based digital and in-person program revenue with clinical services and brand licensing, positioning it at the intersection of the broader weight management industry, which has seen accelerated demand tied to the growing adoption of GLP-1 medications.
- Med+ GLP-1 prescription tier drives subscription revenue growth
- Core membership declines as GLP-1 drugs erode traditional weight loss demand
- Trademark licensing provides stable high-margin revenue amid subscription volatility
| Net Income: -100.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 6.03% < 20% (prev 16.62%; Δ -10.59% < -1%) |
| CFO/TA -0.00 > 3% & CFO -3.75m > Net Income -100.0m |
| Net Debt (327.1m) to EBITDA (102.4m): 3.20 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (10.0m) vs 12m ago 1.05k% < -2% |
| Gross Margin: 67.84% > 18% (prev 70.38%; Δ -2.54% > 0.5%) |
| Asset Turnover: 72.24% > 50% (prev 71.71%; Δ 0.53% > 0%) |
| Interest Coverage Ratio: -0.60 > 6 (EBIT TTM -28.8m / Interest Expense TTM 47.8m) |
| A: 0.05 (Total Current Assets 146.9m - Total Current Liabilities 106.1m) / Total Assets 840.4m |
| B: -0.12 (Retained Earnings -100.0m / Total Assets 840.4m) |
| C: -0.03 (EBIT TTM -28.8m / Avg Total Assets 936.8m) |
| D: 0.50 (Book Value of Equity 278.6m / Total Liabilities 561.8m) |
| Altman-Z'' = 0.24 = B |
| DSRI: 1.49 (Receivables 15.9m/11.7m, Revenue 676.7m/740.9m) |
| GMI: 1.04 (GM 70.38% / 67.84%) |
| AQI: 1.11 (AQ_t 0.81 / AQ_t-1 0.73) |
| SGI: 0.91 (Revenue 676.7m / 740.9m) |
| TATA: -0.11 (NI -100.0m - CFO -3.75m) / TA 840.4m) |
| Beneish M = -2.60 (Cap -4..+1) = A |
As of September 30, 2026, the stock is trading at USD 17.10 with a total of 1,266,381 shares traded. Over the past week, the price has changed by +4.01%, over one month by +2.46%, over three months by +4.27% and over the past year by -37.27%.
Current recommended Stop Loss: 13.90 (which is 18.7% or 2.4 ATR below the current price).
WW International has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold WW.
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.3 | 65.7% |
P/E Trailing = 1.5495
P/E Forward = 74.0741
P/S = 0.2258
P/B = 0.5899
P/EG = 4.9212
Revenue TTM = 676.7m USD
EBIT TTM = -28.8m USD
EBITDA TTM = 102.4m USD
Long Term Debt = 424.0m USD (from longTermDebt, last quarter)
Short Term Debt = 991k USD (from shortTermDebt, last quarter)
Debt = 428.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.32m
Net Debt = 327.1m USD (calculated: Debt 428.6m - CCE 101.5m)
Enterprise Value = 477.4m USD (150.3m + Debt 428.6m - CCE 101.5m)
Interest Coverage Ratio = -0.60 (Ebit TTM -28.8m / Interest Expense TTM 47.8m)
EV/FCF = -17.80x (Enterprise Value 477.4m / FCF TTM -26.8m)
FCF Yield = -5.62% (FCF TTM -26.8m / Enterprise Value 477.4m)
FCF Margin = -3.96% (FCF TTM -26.8m / Revenue TTM 676.7m)
Net Margin = -14.78% (Net Income TTM -100.0m / Revenue TTM 676.7m)
Gross Margin = 67.84% ((Revenue TTM 676.7m - Cost of Revenue TTM 217.7m) / Revenue TTM)
Gross Margin QoQ = 70.72% (prev 58.13%)
Tobins Q-Ratio = 0.57 (Enterprise Value 477.4m / Total Assets 840.4m)
Interest Expense / Debt = 11.15% (Interest Expense 47.8m / Debt 428.6m)
Taxrate = 3.25% (35.4m / 1.09b)
NOPAT = -27.9m (EBIT -28.8m * (1 - 3.25%)) [loss with tax shield]
Current Ratio = 1.38 (Total Current Assets 146.9m / Total Current Liabilities 106.1m)
Debt / Equity = 1.54 (Debt 428.6m / totalStockholderEquity, last quarter 278.6m)
Debt / EBITDA = 3.20 (Net Debt 327.1m / EBITDA 102.4m)
Debt / FCF = -12.19 (negative FCF - burning cash) (Net Debt 327.1m / FCF TTM -26.8m)
Total Stockholder Equity = 296.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.68% (Net Income -100.0m / Total Assets 840.4m)
RoE = -33.75% (Net Income TTM -100.0m / Total Stockholder Equity 296.3m)
RoCE = -4.00% (EBIT -28.8m / Capital Employed (Equity 296.3m + L.T.Debt 424.0m))
RoIC = -3.98% (negative operating profit) (NOPAT -27.9m / Invested Capital 701.5m)
WACC = 11.39% (E(150.3m)/V(578.9m) * Re(13.11%) + D(428.6m)/V(578.9m) * Rd(11.15%) * (1-Tc(0.03)))
Discount Rate = 13.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.35 | Cagr: 199.0%
[DCF] Fair Price = unknown (Cash Flow -26.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.24 | # QB: 0
Revenue Correlation: -99.79 | Revenue CAGR: -10.18% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.84 | Chg30d=-9.97% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.85 | Chg30d=-180.30% | Revisions=+0% | GrowthEPS=-1105.4% | GrowthRev=-11.2%
EPS next Year (2027-12-31): EPS=-0.02 | Chg30d=+83.74% | Revisions=+25% | GrowthEPS=+98.7% | GrowthRev=+1.5%
[Analyst] Revisions Ratio: +0% (up=1, down=1)